Patents by Inventor James W. Mier

James W. Mier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating cancer
    Patent number: 11357742
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 14, 2022
    Assignees: X4 Pharmaceuticals, Inc., Georgetown University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
  • METHODS FOR TREATING CANCER
    Publication number: 20180369167
    Abstract: The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 27, 2018
    Inventors: Robert D. Arbeit, Paula Marie Ragan, Michael B. Atkins, James W. Mier, David McDermott
  • ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma
    Publication number: 20130202594
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
    Type: Application
    Filed: February 1, 2013
    Publication date: August 8, 2013
    Inventors: Rupal S. BHATT, Ravindra Kumar, James W. Mier, Robert Pearsall, Matthew Sherman, Nicolas Solban